冠状动脉钙化(CAC)影像作为诊断试验:保险覆盖的意义
动脉粥样硬化性心血管疾病(ASCVD)是全球首位死因,多数患者首发即为急性事件。过去30年大量研究证实,CAC影像可诊断亚临床冠状动脉疾病(CAD),并在高脂血症、高血压、吸烟、糖尿病等传统危险因素之外预测不良结局。美国心血管专业学会现行ASCVD预防指南推荐先评估危险因素,对临界和中危人群行CAC影像以诊断和量化CAD严重程度、指导治疗,但多数支付方未按指南覆盖CAC检查,导致患者自费、诊断不足和心血管事件预防失败。本文阐述CAC影像的诊断用途,呼吁医疗服务提供者、支付方和政策制定者遵循指南并提供覆盖。
要点
- CAC影像用于诊断亚临床CAD并量化其严重程度,预测不良结局的能力超越传统危险因素。
- 美国心血管专业学会指南推荐对临界危和中危人群在危险因素评估后行CAC影像以指导治疗。
- 多数支付方未按指南覆盖CAC影像,患者需自费,造成诊断不足和心血管事件预防失败。
核心结论
- CAC影像的诊断用途应被支付方覆盖,以支持对无症状CAD患者的共享决策和基于CAD范围的个体化治疗强度。
研究设计与样本
- 本文为学会声明,阐述CAC影像的诊断用途并呼吁遵循ASCVD预防指南提供覆盖,未报告系统检索方法或证据分级。
诊断标准与关键数值
- 美国心血管专业学会现行ASCVD预防指南推荐先评估危险因素筛选可能高危个体,随后对临界危和中危类别行CAC影像以诊断和量化CAD严重程度、指导治疗。
临床应用与阅片要点
- 本文聚焦CAC影像的诊断作用而非其作为全民筛查试验的潜力,并指出全民筛查需大规模结局研究、超出本文范围。
- 作者呼吁医疗服务提供者、支付方和政策制定者遵循ASCVD预防指南并提供覆盖,覆盖CAC的适当诊断用途将使医生能对无症状CAD患者进行共享决策并按CAD范围个体化治疗强度。
局限性
- 本文聚焦CAC影像的诊断作用而非其作为全民筛查试验的潜力。
- 全民筛查虽有理由,但需大规模结局研究,超出本文范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Atherosclerotic cardiovascular disease (ASCVD), in particular atherosclerotic coronary artery disease (CAD), is the leading cause of death in the United States and globally. In the majority of ASCVD victims, the first sign is an acute event (heart attack or stroke) with a high fatality rate. It is widely accepted that most CAD deaths are preventable if asymptomatic at-risk patients are diagnosed and treated before the onset of clinical symptoms. In the past 30 years, numerous studies conclusively demonstrated that coronary artery calcium (CAC) imaging diagnoses patients with subclinical CAD and predicts adverse outcomes beyond conventional risk factors such as hyperlipidemia, hypertension, smoking, and diabetes. Current ASCVD prevention guidelines issued by U.S. cardiovascular professional societies recommend risk factor assessment to screen individuals who may be at risk, followed by CAC imaging in the borderline- and intermediate-risk categories to diagnose and quantify the severity of CAD to guide treatment. However, most payers do not follow these guidelines to cover CAC imaging requiring patients to pay out of pocket, resulting in underdiagnosis and failure to prevent costly cardiovascular events. In this statement, we elaborate on the diagnostic use of CAC imaging and call on health care providers, payers, and policymakers to follow the ASCVD prevention guidelines and provide coverage. Covering the appropriate diagnostic use of CAC will enable physicians to perform shared decision-making for the treatment of patients with asymptomatic CAD and personalize the intensity of the treatment based on the extent of CAD. Specifically, this statement focuses on the diagnostic role of CAC imaging rather than its potential as a universal screening test. Although there are rationales for population-wide screening, such an approach would require large-scale outcome studies and is beyond the scope of this paper.
引用
- Naghavi M, Wong ND, McConnell MV, et al. Coronary Artery Calcium (CAC) Imaging as a Diagnostic Test: Insurance Coverage Implications. JACC Cardiovasc Imaging. 2025. PMID: 41379038. doi:10.1016/j.jcmg.2025.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。